Metagenomi Therapeutics
MGX
79 hedge funds and large institutions have $1.02B invested in Metagenomi Therapeutics in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 8 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 77 → 79 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.53% less ownership
Funds ownership: 28.71% → 26.18% (-2.5%)
52% less capital invested
Capital invested by funds: $2.14B → $1.02B (-$1.12B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$450K |
| 2 |
Millennium Management
New York
|
+$407K |
| 3 |
State Street
Boston,
Massachusetts
|
+$326K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$322K |
| 5 |
BlackRock
New York
|
+$236K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$1.49M |
| 2 |
Morgan Stanley
New York
|
-$1.39M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$540K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$422K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$257K |
MGX Hedge Fund Activity: Q1 2025 in Review
79 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q1 2025, worth a combined $1.02B — down 52% from $2.14B a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MGX positions and 8 closed out — a net gain of 2 holders — while 28 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was HHLR Advisors, cutting an estimated $1.49M.
- 79 institutional investors held Metagenomi Therapeutics (MGX) as of Q1 2025, up from 77 in Q4 2024.
- Funds reported $1.02B of Metagenomi Therapeutics stock for Q1 2025, down 52% quarter-over-quarter.
- 10 funds opened new Metagenomi Therapeutics positions in Q1 2025 and 8 closed out, a net change of +2 holders.
- The largest Metagenomi Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $450K added.
- The largest Metagenomi Therapeutics seller in Q1 2025 was HHLR Advisors, an estimated $1.49M sold.
Based on aggregated 13F filings for Q1 2025.